Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CHMP Recommends Approval of Otsuka’s Delamanid for Treatment of MDR-TB
November 27, 2013
- IFN-Free Hepatitis C Drugs Could Hit Pharmacy Shelves in 2014, New Option for Elderly Patients
November 26, 2013
- Alfresa Pharma Gets Additional Indication for Anafranil
November 26, 2013
- Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
- GSK’s Paxil Granted Japan’s 1st PTSD Indication
November 26, 2013
- Japan’s 1st Acetaminophen IV Injection Now Available
November 26, 2013
- Chugai’s Avastin Approved for Ovarian Cancer Treatment
November 25, 2013
- AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
- Preminent Generics of 30-Plus Firms Likely to Carry “Losarhyd” Brand; Unified Trade Names Logged for 4 More Combination Generics
November 25, 2013
- Kyowa Kirin Launches New PIII Trial for Istradefylline
November 25, 2013
- ASKA Pharmaceutical Plans to Launch Generic Version of Takeda’s Leuplin, Aims for 20% Market Share
November 25, 2013
- Once-Monthly Injectable Abilify Maintena Approved in Europe: Otsuka
November 25, 2013
- Domestic Ethical Drug Market Estimated to Reach 9,617.7 Billion Yen in 2020: Fuji Keizai
November 22, 2013
- Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
- Mid-sized Foreign Drug Makers Eying Full-scale Entry into Japanese Market Encouraged by Favorable Changes in Market Environment; Marketing Systems May Be Key to Success
November 22, 2013
- Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
- Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
- Novartis’ Compliance Advisory Board Holds 1st Meeting amid Diovan Fuss
November 21, 2013
- JT’s Anti-HIV Agent Elvitegravir Wins European Regulatory Approval
November 21, 2013
- Bristol-Myers Italy Head Piras Sworn in as Japan President
November 21, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…